指南与共识神经肿瘤

神经病理学在新诊断胶质母细胞瘤管理中的作用:系统综述与循证临床实践指南

The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline.
指南 / 共识 · J Neurooncol · 2020-11-19

本指南针对成人新诊断或疑似胶质母细胞瘤(GBM),系统综述证据后提出:建议检测IDH1/2突变以辅助分类和预后;55岁以上非经典IDH突变罕见,不推荐普遍测序;IDH野生型WHO II/III级星形细胞瘤应检测EGFR扩增、7号染色体获得/10号染色体缺失和TERT启动子突变以预测GBM样行为;中线浸润性胶质瘤应检测H3-K27M突变。

要点

  • IDH1/2突变检测(IHC和/或测序)建议用于GBM分类和预后。
  • 55岁及以上患者非经典IDH突变罕见,不推荐普遍变异测序。
  • IDH野生型WHO II/III级星形细胞瘤应检测EGFR扩增、7+/10-和TERTp突变。

核心结论

  • IDH1/2突变状态检测有助于成人新诊断GBM的准确分类和预后判断。
  • IDH野生型WHO II/III级星形细胞瘤需检测典型GBM分子改变以预测类似GBM的行为。
  • 中线浸润性胶质瘤应检测H3-K27M突变,因常表现WHO IV级行为。

研究设计与样本

  • 系统综述与循证临床实践指南,针对成人新诊断或疑似胶质母细胞瘤患者。

主要发现

  • 非经典IDH1/2突变在55岁及以上患者中非常罕见。
  • IDH野生型WHO II/III级星形细胞瘤若缺乏GBM组织学标准但具有IDH野生型GBM分子特征,应诊断为弥漫性星形细胞胶质瘤、IDH野生型、伴GBM分子特征、WHO IV级。
  • 中线浸润性胶质瘤即使缺乏胶质母细胞瘤组织学标准,也常表现WHO IV级行为。

关键数值与推荐

  • 建议通过免疫组化(IHC)和/或测序检测IDH1/2突变状态以提供分类和预后信息(Level III)。
  • 不推荐对55岁及以上患者普遍进行非经典IDH1/2变异突变的序列分析(Level III)。
  • 不建议仅凭IDH野生型 designation 将WHO II/III级浸润性星形细胞瘤归为更高级别(Level III)。
  • 建议对IDH野生型WHO II/III级星形细胞瘤检测EGFR扩增、7号染色体获得/10号染色体缺失和TERT启动子突变以证实类似IDH野生型胶质母细胞瘤的行为(Level III)。
  • 建议对缺乏GBM组织学标准但具有IDH野生型GBM分子改变的中线浸润性星形细胞瘤诊断为弥漫性星形细胞胶质瘤、IDH野生型、伴GBM分子特征、WHO IV级(Level III)。

临床怎么用

  • 成人新诊断GBM应常规检测IDH1/2突变状态以辅助分类和预后。
  • 55岁及以上患者不推荐普遍进行非经典IDH变异测序。
  • IDH野生型WHO II/III级星形细胞瘤应检测EGFR扩增、7+/10-和TERTp突变以预测GBM样行为。
  • 中线浸润性胶质瘤应检测H3-K27M突变以指导分级。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

TARGET POPULATION: These recommendations apply to adult patients with newly diagnosed or suspected glioblastoma (GBM) QUESTION : For adult patients with newly diagnosed GBM does testing for Isocitrate Dehydrogenase 1 or 2 (IDH 1/2) mutations afford benefit beyond standard histopathology in providing accurate classification and outcome prognostication? Level III IDH 1/2 mutational status by immunohistochemistry (IHC) and/or sequencing is suggested for classification and prognostic information. Level III Non-canonical IDH 1/2 mutations are very rare in patients aged 55 or older and universal testing of variant mutations by sequence analysis is not suggested for this age range. QUESTION: For adult patients with lower grade infiltrating astrocytomas (WHO grades II and III) can the IDH-wildtype status designation supersede histopathology to predict prognosis and biologic relevance to eventual behavior as a GBM? Level III The designation of infiltrating astrocytomas (WHO grades II and III) as IDH-wildtype is not suggested as sufficient for a higher grade designation alone. Level III It is suggested that IDH-wildtype WHO grades II and III astrocytomas be tested for molecular-genetic alterations typical of IDH-wildtype GBM such as EGFR amplification, gain of chromosome 7/loss of chromosome 10 and TERT-p mutation to substantiate prediction of behavior similar to IDH-wildtype glioblastoma. Level III It is suggested that a diagnosis of diffuse astrocytic glioma, IDH-wildtype, with molecular features of GBM, WHO grade IV be rendered for infiltrating astrocytomas that lack histologic criteria of GBM but harbors molecular-genetic alterations of IDH-wildtype glioblastoma. QUESTION: For adult patients with newly diagnosed infiltrating glioma arising in the midline does testing for H3-K27M mutations provide information beyond that gained by histopathology for accurate classification and outcome prognostication? Level III It is suggested that infiltrating gliomas arising in midline anatomic locations be tested for the H3-K27M mutation as they tend to exhibit WHO grade IV behavior even if they lack histologic criteria for glioblastoma.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Velázquez Vega JE, Brat DJ, Ryken TC, et al. The role of neuropathology in the management of newly diagnosed glioblastoma: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2020. PMID: 33215342. doi:10.1007/s11060-020-03616-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。